Silence Therapeutics Reports Significantly Reduced Q1 Net Loss, Increased Revenue, and Extended Cash Runway into 2028

summarizeSummary

Silence Therapeutics reported a significant reduction in Q1 2026 net loss and increased revenue, extending its cash runway into 2028, despite a partnership termination for one program.

check_boxKey Events

• Net Loss Significantly Reduced

  The company reported a net loss of $(14.957) million for Q1 2026, a substantial improvement from $(28.530) million in Q1 2025.

• Revenue Increased

  Revenue for Q1 2026 rose to $0.422 million, up from $0.142 million in Q1 2025, primarily due to activity with the AstraZeneca collaboration.

• Extended Cash Runway

  Cash and cash equivalents, along with short-term investments, totaled $70.1 million as of March 31, 2026, which the company believes is sufficient to fund operations into 2028.

• AstraZeneca Terminates SLN312 Development

  AstraZeneca notified Silence Therapeutics on March 4, 2026, that it will not pursue further development of SLN312 beyond Phase 1. Silence Therapeutics will regain full development, manufacturing, and commercialization rights globally for this clinical asset.

auto_awesomeAnalysis

Silence Therapeutics plc reported a substantial improvement in its first-quarter 2026 financial results, significantly reducing its net loss and increasing revenue compared to the prior year. Critically, the company announced that its existing cash and short-term investments are sufficient to fund operations into 2028, providing a longer runway for its clinical development programs. While AstraZeneca decided not to pursue further development of SLN312 beyond Phase 1, Silence Therapeutics will regain full rights to this asset, allowing for potential future development or partnering. The company also provided positive updates on its Divesiran and Zerlasiran programs, with Divesiran's Phase 2 topline results expected in August 2026 and Zerlasiran being Phase 3 ready and seeking a partner. These financial and operational updates signal a more stable outlook for the biotech, especially following the more challenging financial baseline reported in the previous 10-K.